Article thumbnail

Twelve-month outcomes in patients with diabetes implanted with a zotarolimus-eluting stent: results from the E-Five Registry

By Ajay K Jain, Chaim Lotan, Ian T Meredith, Faustos Feres, Robaayah Zambahari, Nakul Sinha and Martin T Rothman
Topics: Interventional Cardiology
Publisher: BMJ Group
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2010). A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions: 12-month outcomes from the ENDEAVOR IV trial.
  2. (2007). Clinical endpoints in coronary stent trials: a case for standardized definitions. Circulation
  3. (2007). Comparative clinical outcomes of paclitaxel and sirolimus-eluting stents: Results from a large prospective multicenter registrydSTENT group.
  4. (2007). Comparison of outcomes using sirolimuseluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients.
  5. (2005). Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus- versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries).
  6. (2006). double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for the treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation
  7. (2006). for the ENDEAVOR III Investigators. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial.
  8. Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era.
  9. (2004). Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation
  10. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.
  11. (2007). Long-term clinical outcomes and thrombosis rates of sirolimus-eluting versus paclitaxel-eluting stents in an unselected population with coronary artery disease (REWARDS registry).
  12. (2006). Overview of pharmacology and clinical trials program with the zotarolimus-eluting Endeavor stent.
  13. (2008). Paclitaxel-eluting coronary stents in patients with diabetes mellitus.
  14. (2006). Percutaneous coronary interventions with drug eluting stents for diabetic patients. Heart
  15. Real-world safety and efficacy of the Endeavor zotarolimus-eluting stent: early data from the E-Five registry.
  16. (2009). Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five Registry.
  17. (2006). Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation
  18. (2005). TAXUS-IV Investigators. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial.